-DOCSTART-	O

Title	O
:	O
The	O
CABI	O
Trial	O
:	O
an	O
Unblinded	O
Parallel	O
Group	O
Randomised	O
Controlled	O
Feasibility	O
Trial	O
of	O
Long	B-I
-	I-I
Course	I-I
Antibiotic	I-I
Therapy	I-I
(	O
28	O
Days	O
)	O
Compared	O
with	O
Short	B-I
Course	I-I
(	O
?	O
10	O
Days	O
)	O
in	O
the	O
Prevention	O
of	O
Relapse	O
in	O
Adults	B-P
Treated	I-P
for	I-P
Complicated	I-P
Intra	I-P
-	I-P
Abdominal	I-P
Infection	I-P
.	O

METHODS	O
:	O
A	O
randomised	O
controlled	O
unblinded	O
feasibility	O
trial	O
was	O
conducted	O
.	O

Eligible	O
participants	O
were	O
adult	B-P
patients	I-P
with	I-P
a	I-P
cIAI	I-P
that	I-P
were	I-P
diagnosed	I-P
?	I-P
6	I-P
days	I-P
prior	I-P
to	I-P
screening	I-P
.	O

Randomisation	O
was	O
to	O
long	B-I
-	I-I
course	I-I
(	O
28	O
days	O
)	O
or	O
short	B-I
-	I-I
course	I-I
(	I-I
?10	I-I
days	I-I
)	I-I
antibiotic	I-I
therapy	I-I
.	O

Choice	O
of	O
antibiotics	O
was	O
determined	O
by	O
the	O
clinical	O
team	O
.	O

Participants	O
were	O
followed	O
up	O
for	O
90	O
days	O
.	O

Primary	O
outcomes	O
were	O
willingness	B-O
of	I-O
participants	I-O
to	I-O
be	I-O
randomised	I-O
and	O
feasibility	B-O
of	I-O
trial	I-O
procedures	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
Trial	O
of	O
Lopinavir	B-I
-	O
Ritonavir	B-I
in	O
Adults	B-P
Hospitalized	I-P
with	I-P
Severe	I-P
Covid	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
randomized	O
,	O
controlled	O
,	O
open	O
-	O
label	O
trial	O
involving	O
hospitalized	B-P
adult	I-P
patients	I-P
with	I-P
confirmed	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
infection	I-P
,	I-P
which	I-P
causes	I-P
the	I-P
respiratory	I-P
illness	I-P
Covid	I-P
-	I-P
19	I-P
,	I-P
and	I-P
an	I-P
oxygen	I-P
saturation	I-P
(	I-P
Sao2	I-P
)	I-P
of	I-P
94	I-P
%	I-P
or	I-P
less	I-P
while	I-P
they	I-P
were	I-P
breathing	I-P
ambient	I-P
air	I-P
or	I-P
a	I-P
ratio	I-P
of	I-P
the	I-P
partial	I-P
pressure	I-P
of	I-P
oxygen	I-P
(	I-P
Pao2	I-P
)	I-P
to	I-P
the	I-P
fraction	I-P
of	I-P
inspired	I-P
oxygen	I-P
(	I-P
Fio2	I-P
)	I-P
of	I-P
less	I-P
than	I-P
300	I-P
mm	I-P
Hg	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
in	O
a	O
1	O
:	O
1	O
ratio	O
to	O
receive	O
either	O
lopinavir	B-I
-	O
ritonavir	B-I
(	O
400	O
mg	O
and	O
100	O
mg	O
,	O
respectively	O
)	O
twice	O
a	O
day	O
for	O
14	O
days	O
,	O
in	O
addition	O
to	O
standard	B-I
care	I-I
,	O
or	O
standard	B-C
care	I-C
alone	I-C
.	O

The	O
primary	O
end	O
point	O
was	O
the	B-O
time	I-O
to	I-O
clinical	I-O
improvement	I-O
,	O
defined	O
as	O
the	B-O
time	I-O
from	I-O
randomization	I-O
to	I-O
either	I-O
an	I-O
improvement	I-O
of	I-O
two	I-O
points	I-O
on	O
a	B-O
seven	I-O
-	I-O
category	I-O
ordinal	I-O
scale	I-O
or	O
discharge	B-O
from	I-O
the	I-O
hospital	I-O
,	O
whichever	O
came	O
first	O
.	O

-DOCSTART-	O

Title	O
:	O
Respiratory	B-I
rehabilitation	I-I
in	O
elderly	B-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
randomized	O
controlled	O
study	O
.	O

METHODS	O
:	O
This	O
paper	O
reported	O
the	O
findings	O
of	O
an	O
observational	O
,	O
prospective	O
,	O
quasi	O
-	O
experimental	O
study	O
,	O
which	O
totally	O
recruited	O
72	B-P
participants	I-P
,	O
of	O
which	O
36	O
patients	O
underwent	O
respiratory	B-I
rehabilitation	I-I
and	O
the	O
rest	O
without	O
any	B-C
rehabilitation	I-C
intervention	I-C
.	O

The	O
following	O
outcomes	O
were	O
measured	O
:	O
pulmonary	B-O
function	I-O
tests	I-O
including	O
plethysmography	B-O
and	O
diffusing	B-O
lung	I-O
capacity	I-O
for	I-O
carbon	I-O
monoxide	I-O
(	I-O
DLCO	I-O
)	I-O
,	O
functional	B-O
tests	I-O
(	O
6	B-O
-	I-O
min	I-O
walk	I-O
distance	I-O
test	I-O
)	O
,	O
Quality	B-O
of	I-O
life	I-O
(	I-O
QoL	I-O
)	I-O
assessments	I-O
(	O
SF	B-O
-	I-O
36	I-O
scores	I-O
)	O
,	O
activities	B-O
of	I-O
daily	I-O
living	I-O
(	O
Functional	B-O
Independence	I-O
Measure	I-O
,	O
FIM	B-O
scores	I-O
)	O
,	O
and	O
mental	B-O
status	I-O
tests	I-O
(	O
SAS	B-O
anxiety	I-O
and	O
SDS	B-O
depression	I-O
scores	I-O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
progressive	B-I
muscle	I-I
relaxation	I-I
on	O
anxiety	O
and	O
sleep	O
quality	O
in	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
In	O
this	O
randomized	O
controlled	O
clinical	O
trial	O
,	O
a	B-P
total	I-P
of	I-P
51	I-P
patients	I-P
who	I-P
entered	I-P
the	I-P
isolation	I-P
ward	I-P
were	O
included	O
in	O
the	O
study	O
and	O
randomly	O
divided	O
into	O
experimental	O
and	O
control	O
groups	O
.	O

The	O
experimental	O
group	O
used	O
progressive	B-I
muscle	I-I
relaxation	I-I
(	I-I
PMR	I-I
)	I-I
technology	I-I
for	O
30	O
min	O
per	O
day	O
for	O
5	O
consecutive	O
days	O
.	O

During	O
this	O
period	O
,	O
the	O
control	O
group	O
received	O
only	B-C
routine	I-C
care	I-C
and	O
treatment	B-C
.	O

Before	O
and	O
after	O
the	O
intervention	O
,	O
the	B-O
Spielberger	I-O
State	I-O
-	I-O
Trait	I-O
Anxiety	I-O
Scale	I-O
(	I-O
STAI	I-O
)	I-O
and	O
Sleep	B-O
State	I-O
Self	I-O
-	I-O
Rating	I-O
Scale	I-O
(	I-O
SRSS	I-O
)	I-O
were	O
used	O
to	O
measure	O
and	O
record	O
patient	B-O
anxiety	I-O
and	O
sleep	B-O
quality	I-O
.	O

Finally	O
,	O
data	O
analysis	O
was	O
performed	O
using	O
SPSS	O
25	O
.	O
0	O
software	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
A	O
pilot	O
study	O
of	O
hydroxychloroquine	B-I
in	O
treatment	O
of	O
patients	B-P
with	I-P
moderate	I-P
COVID	I-P
-	I-P
19	I-P
]	O
.	O

METHODS	O
:	O
We	O
prospectively	O
enrolled	O
30	B-P
treatment	I-P
-	I-P
nave	I-P
patients	I-P
with	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
after	I-P
informed	I-P
consent	I-P
at	I-P
Shanghai	I-P
Public	I-P
Health	I-P
Clinical	I-P
Center	I-P
.	O

The	O
patients	O
were	O
randomized	O
1?1	O
to	O
HCQ	B-I
group	O
and	O
the	O
control	O
group	O
.	O

Patients	O
in	O
HCQ	B-I
group	O
were	O
given	O
HCQ	B-I
400	O
mg	O
per	O
day	O
for	O
5	O
days	O
plus	O
conventional	B-I
treatments	I-I
,	O
while	O
those	O
in	O
the	O
control	O
group	O
were	O
given	O
conventional	B-C
treatment	I-C
only	I-C
.	O

The	O
primary	O
endpoint	O
was	O
negative	B-O
conversion	I-O
rate	I-O
of	I-O
SARS	I-O
-	I-O
CoV	I-O
-	I-O
2	I-O
nucleic	I-O
acid	I-O
in	I-O
respiratory	I-O
pharyngeal	I-O
swab	I-O
on	O
days	O
7	O
after	O
randomization	O
.	O

This	O
study	O
has	O
been	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
Shanghai	O
Public	O
Health	O
Clinical	O
Center	O
and	O
registered	O
online	O
(	O
NCT04261517	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Triple	O
combination	O
of	O
interferon	B-I
beta	I-I
-	I-I
1	I-I
b	I-I
,	O
lopinavir	B-I
-	O
ritonavir	B-I
,	O
and	O
ribavirin	B-I
in	O
the	O
treatment	O
of	O
patients	B-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
an	O
open	O
-	O
label	O
,	O
randomised	O
,	O
phase	O
2	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
multicentre	O
,	O
prospective	O
,	O
open	O
-	O
label	O
,	O
randomised	O
,	O
phase	O
2	O
trial	O
in	O
adults	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
who	I-P
were	I-P
admitted	I-P
to	I-P
six	I-P
hospitals	I-P
in	I-P
Hong	I-P
Kong	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
(	O
2	O
:	O
1	O
)	O
to	O
a	B-I
14	I-I
-	I-I
day	I-I
combination	I-I
of	I-I
lopinavir	I-I
400	O
mg	O
and	O
ritonavir	B-I
100	O
mg	O
every	O
12	O
h	O
,	O
ribavirin	B-I
400	O
mg	O
every	O
12	O
h	O
,	O
and	O
three	B-I
doses	I-I
of	I-I
8	I-I
million	I-I
international	I-I
units	I-I
of	I-I
interferon	I-I
beta	I-I
-	I-I
1	I-I
b	I-I
on	O
alternate	O
days	O
(	O
combination	O
group	O
)	O
or	O
to	O
14	B-C
days	I-C
of	I-C
lopinavir	I-C
400	O
mg	O
and	O
ritonavir	B-C
100	O
mg	O
every	O
12	O
h	O
(	O
control	O
group	O
)	O
.	O

The	O
primary	O
endpoint	O
was	O
the	B-O
time	I-O
to	I-O
providing	I-O
a	I-O
nasopharyngeal	I-O
swab	I-O
negative	I-O
for	I-O
severe	I-O
acute	I-O
respiratory	I-O
syndrome	I-O
coronavirus	I-O
2	I-O
RT	I-O
-	I-O
PCR	I-O
,	O
and	O
was	O
done	O
in	O
the	O
intention	O
-	O
to	O
-	O
treat	O
population	O
.	O

The	O
study	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT04276688	O
.	O

-DOCSTART-	O

Title	O
:	O
Hydroxychloroquine	B-I
in	O
patients	B-P
with	I-P
mainly	I-P
mild	I-P
to	I-P
moderate	I-P
coronavirus	I-P
disease	I-P
2019	I-P
:	O
open	O
label	O
,	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Multicentre	O
,	O
open	O
label	O
,	O
randomised	O
controlled	O
trial	O
.	O

16	O
government	O
designated	O
covid	O
-	O
19	O
treatment	O
centres	O
in	O
China	O
,	O
11	O
to	O
29	O
February	O
2020	O
.	O

150	B-P
patients	I-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
laboratory	I-P
confirmed	I-P
covid	I-P
-	I-P
19	I-P
were	O
included	O
in	O
the	O
intention	O
to	O
treat	O
analysis	O
(	O
75	O
patients	O
assigned	O
to	O
hydroxychloroquine	B-I
plus	O
standard	B-I
of	I-I
care	I-I
,	O
75	O
to	O
standard	B-C
of	I-C
care	I-C
alone	I-C
)	O
.	O

Hydroxychloroquine	B-I
administrated	O
at	O
a	O
loading	O
dose	O
of	O
1200	O
mg	O
daily	O
for	O
three	O
days	O
followed	O
by	O
a	O
maintenance	O
dose	O
of	O
800	O
mg	O
daily	O
(	O
total	O
treatment	O
duration	O
:	O
two	O
or	O
three	O
weeks	O
for	O
patients	O
with	O
mild	O
to	O
moderate	O
or	O
severe	O
disease	O
,	O
respectively	O
)	O
.	O

Negative	B-O
conversion	I-O
of	I-O
severe	I-O
acute	I-O
respiratory	I-O
syndrome	I-O
coronavirus	I-O
2	I-O
by	O
28	O
days	O
,	O
analysed	O
according	O
to	O
the	O
intention	O
to	O
treat	O
principle	O
.	O

Adverse	B-O
events	I-O
were	O
analysed	O
in	O
the	O
safety	O
population	O
in	O
which	O
hydroxychloroquine	B-I
recipients	O
were	O
participants	O
who	O
received	O
at	O
least	O
one	B-I
dose	I-I
of	I-I
hydroxychloroquine	I-I
and	O
hydroxychloroquine	B-I
non	O
-	O
recipients	O
were	O
those	O
managed	O
with	O
standard	O
of	O
care	O
alone	O
.	O

-DOCSTART-	O

Title	O
:	O
Remdesivir	B-I
in	O
adults	B-P
with	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
:	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
multicentre	O
trial	O
.	O

METHODS	O
:	O
We	O
did	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
multicentre	O
trial	O
at	O
ten	O
hospitals	O
in	O
Hubei	O
,	O
China	O
.	O

Eligible	O
patients	O
were	O
adults	B-P
(	I-P
aged	I-P
?18	I-P
years	I-P
)	I-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
laboratory	I-P
-	I-P
confirmed	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
infection	I-P
,	I-P
with	I-P
an	I-P
interval	I-P
from	I-P
symptom	I-P
onset	I-P
to	I-P
enrolment	I-P
of	I-P
12	I-P
days	I-P
or	I-P
less	I-P
,	I-P
oxygen	I-P
saturation	I-P
of	I-P
94	I-P
%	I-P
or	I-P
less	I-P
on	I-P
room	I-P
air	I-P
or	I-P
a	I-P
ratio	I-P
of	I-P
arterial	I-P
oxygen	I-P
partial	I-P
pressure	I-P
to	I-P
fractional	I-P
inspired	I-P
oxygen	I-P
of	I-P
300	I-P
mm	I-P
Hg	I-P
or	I-P
less	I-P
,	I-P
and	I-P
radiologically	I-P
confirmed	I-P
pneumonia	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
in	O
a	O
2	O
:	O
1	O
ratio	O
to	O
intravenous	B-I
remdesivir	I-I
(	O
200	O
mg	O
on	O
day	O
1	O
followed	O
by	O
100	O
mg	O
on	O
days	O
2	O
-	O
10	O
in	O
single	O
daily	O
infusions	O
)	O
or	O
the	B-C
same	I-C
volume	I-C
of	I-C
placebo	I-C
infusions	O
for	O
10	O
days	O
.	O

Patients	O
were	O
permitted	O
concomitant	O
use	O
of	O
lopinavir	O
-	O
ritonavir	O
,	O
interferons	O
,	O
and	O
corticosteroids	O
.	O

The	O
primary	O
endpoint	O
was	O
time	B-O
to	I-O
clinical	I-O
improvement	I-O
up	O
to	O
day	O
28	O
,	O
defined	O
as	O
the	B-O
time	I-O
(	I-O
in	I-O
days	I-O
)	I-O
from	I-O
randomisation	I-O
to	I-O
the	I-O
point	I-O
of	I-O
a	I-O
decline	I-O
of	I-O
two	I-O
levels	I-O
on	O
a	B-O
six	I-O
-	I-O
point	I-O
ordinal	I-O
scale	I-O
of	I-O
clinical	I-O
status	I-O
(	O
from	O
1	O
=	O
discharged	O
to	O
6	O
=	O
death	O
)	O
or	O
discharged	B-O
alive	I-O
from	I-O
hospital	I-O
,	O
whichever	O
came	O
first	O
.	O

Primary	O
analysis	O
was	O
done	O
in	O
the	O
intention	O
-	O
to	O
-	O
treat	O
(	O
ITT	O
)	O
population	O
and	O
safety	O
analysis	O
was	O
done	O
in	O
all	O
patients	O
who	O
started	O
their	O
assigned	O
treatment	O
.	O

This	O
trial	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT04257656	O
.	O

-DOCSTART-	O

Title	O
:	O
Remdesivir	B-I
for	O
the	O
Treatment	O
of	O
Covid	O
-	O
19	O
-	O
Final	O
Report	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
intravenous	B-I
remdesivir	I-I
in	O
adults	B-P
who	I-P
were	I-P
hospitalized	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
and	I-P
had	I-P
evidence	I-P
of	I-P
lower	I-P
respiratory	I-P
tract	I-P
infection	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
remdesivir	B-I
(	O
200	O
mg	O
loading	O
dose	O
on	O
day	O
1	O
,	O
followed	O
by	O
100	O
mg	O
daily	O
for	O
up	O
to	O
9	O
additional	O
days	O
)	O
or	O
placebo	B-C
for	O
up	O
to	O
10	O
days	O
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
time	I-O
to	I-O
recovery	I-O
,	O
defined	O
by	O
either	O
discharge	B-O
from	I-O
the	I-O
hospital	I-O
or	O
hospitalization	B-O
for	I-O
infection	I-O
-	I-O
control	I-O
purposes	I-O
only	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Ruxolitinib	B-I
in	O
treatment	O
of	O
severe	O
coronavirus	O
disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
:	O
A	O
multicenter	O
,	O
single	O
-	O
blind	O
,	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
prospective	O
,	O
multicenter	O
,	O
single	O
-	O
blind	O
,	O
randomized	O
controlled	O
phase	O
II	O
trial	O
involving	O
patients	B-P
with	I-P
severe	I-P
coronavirus	I-P
disease	I-P
2019	I-P
.	O

-DOCSTART-	O

Title	O
:	O
A	O
Randomized	O
Trial	O
of	O
Hydroxychloroquine	B-I
as	O
Postexposure	O
Prophylaxis	O
for	O
Covid	O
-	O
19	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
across	O
the	O
United	O
States	O
and	O
parts	O
of	O
Canada	O
testing	O
hydroxychloroquine	B-I
as	O
postexposure	O
prophylaxis	O
.	O

We	O
enrolled	O
adults	B-P
who	I-P
had	I-P
household	I-P
or	I-P
occupational	I-P
exposure	I-P
to	I-P
someone	I-P
with	I-P
confirmed	I-P
Covid	I-P
-	I-P
19	I-P
at	I-P
a	I-P
distance	I-P
of	I-P
less	I-P
than	I-P
6	I-P
ft	I-P
for	I-P
more	I-P
than	I-P
10	I-P
minutes	I-P
while	I-P
wearing	I-P
neither	I-P
a	I-P
face	I-P
mask	I-P
nor	I-P
an	I-P
eye	I-P
shield	I-P
(	I-P
high	I-P
-	I-P
risk	I-P
exposure	I-P
)	I-P
or	I-P
while	I-P
wearing	I-P
a	I-P
face	I-P
mask	I-P
but	I-P
no	I-P
eye	I-P
shield	I-P
(	I-P
moderate	I-P
-	I-P
risk	I-P
exposure	I-P
)	I-P
.	O

Within	O
4	O
days	O
after	O
exposure	O
,	O
we	O
randomly	O
assigned	O
participants	O
to	O
receive	O
either	O
placebo	B-C
or	O
hydroxychloroquine	B-I
(	O
800	O
mg	O
once	O
,	O
followed	O
by	O
600	O
mg	O
in	O
6	O
to	O
8	O
hours	O
,	O
then	O
600	O
mg	O
daily	O
for	O
4	O
additional	O
days	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
incidence	I-O
of	I-O
either	I-O
laboratory	I-O
-	I-O
confirmed	I-O
Covid	I-O
-	I-O
19	I-O
or	O
illness	B-O
compatible	I-O
with	I-O
Covid	I-O
-	I-O
19	I-O
within	O
14	O
days	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Effect	O
of	O
Xuebijing	B-I
injection	I-I
on	O
inflammatory	O
markers	O
and	O
disease	O
outcome	O
of	O
coronavirus	O
disease	O
2019	O
]	O
.	O

METHODS	O
:	O
Sixty	B-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
admitted	I-P
to	I-P
Changsha	I-P
Public	I-P
Health	I-P
Treatment	I-P
Center	I-P
(	I-P
North	I-P
Hospital	I-P
of	I-P
the	I-P
First	I-P
Hospital	I-P
of	I-P
Changsha	I-P
City	I-P
)	I-P
from	I-P
January	I-P
to	I-P
March	I-P
in	I-P
2020	I-P
were	O
randomly	O
divided	O
into	O
routine	B-C
treatment	I-C
group	O
,	O
Xuebijing	B-I
50	O
mL	O
group	O
and	O
Xuebijing	B-I
100	O
mL	O
group	O
,	O
with	O
20	O
cases	O
in	O
each	O
group	O
.	O

The	O
routine	O
treatment	O
group	O
was	O
treated	O
according	O
to	O
the	O
National	O
Health	O
Commission	O
'	O
s	O
guide	O
for	O
COVID	O
-	O
19	O
.	O

On	O
the	O
basis	O
of	O
conventional	O
treatment	O
,	O
Xuebijing	B-I
injection	O
was	O
injected	O
by	O
50	O
mL	O
twice	O
a	O
day	O
for	O
7	O
days	O
in	O
Xuebijing	B-I
50	O
mL	O
group	O
,	O
while	O
by	O
100	O
mL	O
twice	O
a	O
day	O
for	O
7	O
days	O
in	O
Xuebijing	B-I
100	O
mL	O
group	O
.	O

The	B-O
blood	I-O
routine	I-O
test	I-O
,	O
C	B-O
-	I-O
reactive	I-O
protein	I-O
(	I-O
CRP	I-O
)	I-O
,	O
erythrocyte	B-O
sedimentation	I-O
rate	I-O
(	I-O
ESR	I-O
)	I-O
,	O
acute	B-O
physiology	I-O
and	O
chronic	B-O
health	I-O
evaluation	I-O
II	I-O
(	I-O
APACHE	I-O
II	I-O
)	I-O
score	I-O
,	O
2019	B-O
novel	I-O
coronavirus	I-O
(	I-O
2019	I-O
-	I-O
nCoV	I-O
)	I-O
nucleic	I-O
acid	I-O
test	I-O
and	O
disease	B-O
classification	I-O
of	O
three	O
groups	O
before	O
and	O
8	O
days	O
after	O
treatment	O
were	O
observed	O
.	O

-DOCSTART-	O

Title	O
:	O
Oseltamivir	B-I
for	O
coronavirus	O
illness	O
:	O
post	O
-	O
hoc	O
exploratory	O
analysis	O
of	O
an	O
open	O
-	O
label	O
,	O
pragmatic	O
,	O
randomised	O
controlled	O
trial	O
in	O
European	O
primary	O
care	O
from	O
2016	O
to	O
2018	O
.	O

METHODS	O
:	O
Exploratory	O
analysis	O
of	O
data	O
from	O
an	O
open	O
-	O
label	O
,	O
pragmatic	O
,	O
randomised	O
controlled	O
trial	O
during	O
three	O
influenza	O
seasons	O
,	O
from	O
2016	O
to	O
2018	O
,	O
in	O
primary	O
care	O
research	O
networks	O
,	O
in	O
15	O
European	O
countries	O
.	O

Patients	B-P
aged	I-P
?1	I-P
year	I-P
presenting	I-P
to	I-P
primary	I-P
care	I-P
with	I-P
influenza	I-P
-	I-P
like	I-P
illness	I-P
(	I-P
ILI	I-P
)	I-P
,	I-P
and	I-P
who	I-P
tested	I-P
positive	I-P
for	I-P
coronavirus	I-P
(	I-P
not	I-P
including	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
)	I-P
,	O
were	O
randomised	O
to	O
usual	B-C
care	I-C
or	O
usual	B-I
care	I-I
plus	O
oseltamivir	B-I
.	O

The	O
primary	O
outcome	O
was	O
time	B-O
to	I-O
recovery	I-O
defined	O
as	O
a	B-O
return	I-O
to	I-O
usual	I-O
activities	I-O
,	O
with	O
minor	B-O
or	O
absent	B-O
fever	I-O
,	O
headache	B-O
,	O
and	O
muscle	B-O
ache	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Febuxostat	B-I
therapy	I-I
in	O
outpatients	B-P
with	I-P
suspected	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
clinical	O
trial	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
clinical	O
trial	O
involving	O
adult	B-P
outpatients	I-P
with	I-P
the	I-P
moderate	I-P
respiratory	I-P
illness	I-P
following	I-P
COVID	I-P
-	I-P
19	I-P
infection	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
FBX	B-I
or	O
HCQ	B-I
for	O
5	O
days	O
.	O

The	O
measured	O
variables	O
were	O
needs	B-O
to	I-O
hospitalisation	I-O
,	O
clinical	B-O
and	O
laboratory	B-O
data	I-O
including	O
fever	B-O
,	O
cough	B-O
,	O
breathing	B-O
rate	I-O
,	O
C	B-O
-	I-O
Reactive	I-O
Protein	I-O
level	I-O
,	O
lymphocytes	B-O
count	I-O
at	O
onset	O
of	O
admission	O
and	O
was	O
well	O
as	O
at	O
5	O
days	O
of	O
treatments	O
.	O

In	O
addition	O
,	O
CT	B-O
findings	I-O
were	O
evaluated	O
on	O
admission	O
and	O
14	O
days	O
after	O
initiation	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Intravenous	B-I
high	I-I
-	I-I
dose	I-I
vitamin	I-I
C	I-I
for	O
the	O
treatment	O
of	O
severe	O
COVID	O
-	O
19	O
:	O
study	O
protocol	O
for	O
a	O
multicentre	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
The	O
investigators	O
designed	O
a	O
multicentre	O
prospective	O
randomised	O
placebo	O
-	O
controlled	O
trial	O
that	O
is	O
planned	O
to	O
recruit	O
308	B-P
adults	I-P
diagnosed	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
transferred	I-P
into	I-P
the	I-P
intensive	I-P
care	I-P
unit	I-P
.	O

Participants	O
will	O
randomly	O
receive	O
HIVC	B-I
diluted	O
in	O
sterile	O
water	O
or	O
placebo	B-C
for	O
7	O
days	O
once	O
enrolled	O
.	O

Patients	O
with	O
a	O
history	O
of	O
VC	O
allergy	O
,	O
end	O
-	O
stage	O
pulmonary	O
disease	O
,	O
advanced	O
malignancy	O
or	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
deficiency	O
will	O
be	O
excluded	O
.	O

The	O
primary	O
outcome	O
is	O
ventilation	B-O
-	I-O
free	I-O
days	I-O
within	O
28	O
observational	O
days	O
.	O

This	O
is	O
one	O
of	O
the	O
first	O
clinical	O
trials	O
applying	O
HIVC	B-I
to	O
treat	O
COVID	O
-	O
19	O
,	O
and	O
it	O
will	O
provide	O
credible	O
efficacy	O
and	O
safety	O
data	O
.	O

We	O
predict	O
that	O
HIVC	B-I
could	O
suppress	O
cytokine	O
storms	O
caused	O
by	O
COVID	O
-	O
19	O
,	O
help	O
improve	O
pulmonary	O
function	O
and	O
reduce	O
the	O
risk	O
of	O
ARDS	O
of	O
COVID	O
-	O
19	O
.	O
